Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 64; no. 7 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
23.06.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 1098-6596 |
| DOI | 10.1128/AAC.00819-20 |
Cover
| Abstract | Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC
50
s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC
50
s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. |
|---|---|
| AbstractList | Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects. Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects. |
| Author | Lee, Jihye Byun, Soo Young Kim, Seungtaek Park, Soonju Ko, Meehyun Jeon, Sangeun Choi, Inhee Shum, David |
| Author_xml | – sequence: 1 givenname: Sangeun surname: Jeon fullname: Jeon, Sangeun organization: Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea – sequence: 2 givenname: Meehyun surname: Ko fullname: Ko, Meehyun organization: Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea – sequence: 3 givenname: Jihye surname: Lee fullname: Lee, Jihye organization: Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea – sequence: 4 givenname: Inhee surname: Choi fullname: Choi, Inhee organization: Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea – sequence: 5 givenname: Soo Young surname: Byun fullname: Byun, Soo Young organization: Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea – sequence: 6 givenname: Soonju surname: Park fullname: Park, Soonju organization: Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea – sequence: 7 givenname: David surname: Shum fullname: Shum, David organization: Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea – sequence: 8 givenname: Seungtaek surname: Kim fullname: Kim, Seungtaek organization: Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32366720$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUtr3DAUhUVJaSaPXdfFywaqVA9LljcB4zRtIFBImmyFRo-pgi1NJHsg_z7KTBra0q7ERd89nHPPAdgLMVgA3mN0ijERn7uuP0VI4BYS9AYsMGoF5Kzle2CBEOewFqjeBwc536Mysxa9A_uUUM4bghbg7tLYMHnntZp8DFV0VVfmjU9qqM7TvKp6FYw3arK5UivlQ56qm-76BvbxDpLKpThWF-cd7NbrFDfWbJfyEXjr1JDt8ct7CG4vvvzov8Gr718v--4KqlrUE-TCOFYzYZpacyqa2inEHNNaY4x4Q5eWtYZqvWRcKyMINhovhaM1VlhYq-khONvpruflaI0uWYpxuU5-VOlRRuXlnz_B_5SruJENxQIxUgQ-vgik-DDbPMnRZ22HQQUb5ywJbQWnGPNn9GSHqjwSeR_nFEo0iZF87kGWHuS2B0lQYT_87uvV0K_DF-DTDtAp5pyse0X-o0f-wrWfto2VVH7499ITjcqi1g |
| CitedBy_id | crossref_primary_10_1038_s41597_022_01532_x crossref_primary_10_3390_microorganisms10081639 crossref_primary_10_1093_infdis_jiab305 crossref_primary_10_1016_j_crphar_2021_100072 crossref_primary_10_1016_j_pscia_2022_100002 crossref_primary_10_1093_bib_bbab249 crossref_primary_10_5582_ddt_2023_01078 crossref_primary_10_1093_jmcb_mjad017 crossref_primary_10_1126_sciadv_abo5400 crossref_primary_10_1016_j_tim_2021_01_014 crossref_primary_10_1111_jcmm_15927 crossref_primary_10_3390_v14081734 crossref_primary_10_1016_j_jaci_2020_09_004 crossref_primary_10_1007_s40256_020_00429_7 crossref_primary_10_1128_CMR_00109_21 crossref_primary_10_3390_ph17121668 crossref_primary_10_1007_s11154_021_09692_8 crossref_primary_10_3390_pharmaceutics14010176 crossref_primary_10_1093_bib_bbac326 crossref_primary_10_3390_ijms23094809 crossref_primary_10_3389_fphar_2023_1193282 crossref_primary_10_1016_j_virusres_2020_198176 crossref_primary_10_1038_s41598_020_72879_7 crossref_primary_10_1183_16000617_0099_2022 crossref_primary_10_1016_j_jiph_2024_03_030 crossref_primary_10_3390_v14020374 crossref_primary_10_1186_s12889_024_17747_z crossref_primary_10_3390_life12020153 crossref_primary_10_1080_13543776_2021_1880568 crossref_primary_10_1038_s41579_024_01036_y crossref_primary_10_1021_acs_jproteome_0c00397 crossref_primary_10_3389_fddsv_2022_1082065 crossref_primary_10_1089_hs_2022_0132 crossref_primary_10_1042_EBC20200129 crossref_primary_10_1016_j_metop_2021_100103 crossref_primary_10_1002_prp2_1233 crossref_primary_10_1038_s41598_022_21984_w crossref_primary_10_4155_fmc_2021_0025 crossref_primary_10_1016_j_actpha_2020_08_007 crossref_primary_10_1038_s41551_021_00718_9 crossref_primary_10_1080_07391102_2023_2240419 crossref_primary_10_3389_fphar_2022_955648 crossref_primary_10_3390_stresses3030043 crossref_primary_10_1016_j_rmed_2020_106275 crossref_primary_10_3389_fchem_2022_933102 crossref_primary_10_1126_science_abi4708 crossref_primary_10_3390_v13040651 crossref_primary_10_1016_j_apsb_2021_09_008 crossref_primary_10_1128_spectrum_01399_24 crossref_primary_10_3390_ijms22137071 crossref_primary_10_3389_fphar_2020_582310 crossref_primary_10_1021_acs_jmedchem_1c01372 crossref_primary_10_1016_j_clinthera_2021_02_003 crossref_primary_10_1093_bib_bbab211 crossref_primary_10_1007_s00044_020_02610_8 crossref_primary_10_1111_bcp_14668 crossref_primary_10_1111_cmi_13319 crossref_primary_10_2217_fmb_2021_0019 crossref_primary_10_2147_AABC_S366111 crossref_primary_10_1007_s12038_020_00067_w crossref_primary_10_1016_j_biopha_2023_114614 crossref_primary_10_1080_07391102_2021_2000498 crossref_primary_10_1016_j_jiac_2024_08_020 crossref_primary_10_1007_s13205_021_02644_8 crossref_primary_10_1016_j_carbpol_2022_119500 crossref_primary_10_1136_bmjopen_2022_064374 crossref_primary_10_3390_cimb46070395 crossref_primary_10_1021_acsinfecdis_0c00349 crossref_primary_10_1016_j_bmcl_2024_130015 crossref_primary_10_3390_pathogens10091076 crossref_primary_10_1371_journal_pone_0294872 crossref_primary_10_3390_ph15121448 crossref_primary_10_1016_j_ejmech_2022_114295 crossref_primary_10_1021_acsinfecdis_0c00343 crossref_primary_10_1080_15548627_2022_2116677 crossref_primary_10_2174_0113895575311618240820103549 crossref_primary_10_14233_ajchem_2020_22891 crossref_primary_10_1016_j_crphar_2021_100045 crossref_primary_10_1007_s12272_023_01458_x crossref_primary_10_3390_ph14040332 crossref_primary_10_1021_acsinfecdis_0c00478 crossref_primary_10_1186_s12863_022_01040_2 crossref_primary_10_1371_journal_ppat_1009898 crossref_primary_10_3390_ijms242115894 crossref_primary_10_1093_bib_bbab350 crossref_primary_10_1093_bib_bbaa260 crossref_primary_10_3389_fmolb_2021_671263 crossref_primary_10_1016_j_coviro_2021_08_007 crossref_primary_10_1109_ACCESS_2021_3093633 crossref_primary_10_1016_j_molliq_2022_118775 crossref_primary_10_1089_can_2022_0018 crossref_primary_10_1080_10717544_2022_2118398 crossref_primary_10_1111_all_14471 crossref_primary_10_1007_s00705_024_06097_1 crossref_primary_10_1016_S2213_2600_21_00095_3 crossref_primary_10_1128_mBio_02839_20 crossref_primary_10_1016_j_celrep_2020_107940 crossref_primary_10_3390_ph14050486 crossref_primary_10_1016_j_ncrna_2022_01_003 crossref_primary_10_1016_j_ymthe_2024_03_029 crossref_primary_10_1016_j_virusres_2020_198277 crossref_primary_10_1016_j_waojou_2021_100576 crossref_primary_10_1055_a_2416_2329 crossref_primary_10_1093_jmcb_mjab002 crossref_primary_10_3390_jpm11121374 crossref_primary_10_1128_AAC_01146_20 crossref_primary_10_1016_j_bmc_2020_115757 crossref_primary_10_1002_vjch_202100187 crossref_primary_10_1007_s11094_021_02308_0 crossref_primary_10_3389_fmicb_2022_1031204 crossref_primary_10_1038_s41467_020_19055_7 crossref_primary_10_1371_journal_pone_0281981 crossref_primary_10_1016_S2589_7500_20_30192_8 crossref_primary_10_1111_jcpt_13390 crossref_primary_10_1186_s13063_023_07128_z crossref_primary_10_1038_s41467_023_37572_z crossref_primary_10_1038_s41598_021_84700_0 crossref_primary_10_3390_ph14070691 crossref_primary_10_1016_j_micres_2023_127364 crossref_primary_10_1007_s12010_023_04439_4 crossref_primary_10_1038_s41421_020_00192_8 crossref_primary_10_1016_j_celrep_2021_108959 crossref_primary_10_1111_cts_13833 crossref_primary_10_21518_2079_701X_2022_16_18_122_130 crossref_primary_10_3390_v13050869 crossref_primary_10_2174_0115680266276749240206101847 crossref_primary_10_1038_s41380_021_01309_5 crossref_primary_10_3389_fviro_2022_956113 crossref_primary_10_1021_acsomega_3c02921 crossref_primary_10_1016_j_jiph_2023_06_017 crossref_primary_10_1099_jgv_0_001838 crossref_primary_10_1021_acs_jmedchem_1c01758 crossref_primary_10_1128_aac_01233_24 crossref_primary_10_1093_database_baab017 crossref_primary_10_3390_pharmaceutics13040488 crossref_primary_10_1021_acs_jmedchem_1c00665 crossref_primary_10_1021_acs_jmedchem_1c00302 crossref_primary_10_3390_v15112161 crossref_primary_10_3390_pharmaceutics14122632 crossref_primary_10_1111_cts_12975 crossref_primary_10_1186_s43556_021_00050_3 crossref_primary_10_1186_s12890_022_02168_8 crossref_primary_10_2174_1386207323666200814132149 crossref_primary_10_1016_j_scp_2022_100639 crossref_primary_10_1016_j_mtcomm_2024_109202 crossref_primary_10_1016_j_jconrel_2023_07_016 crossref_primary_10_1002_med_21724 crossref_primary_10_3390_pharmaceutics13071077 crossref_primary_10_1371_journal_ppat_1009840 crossref_primary_10_1016_j_micpath_2023_105994 crossref_primary_10_1080_10286020_2023_2197595 crossref_primary_10_3389_fsysb_2022_815237 crossref_primary_10_1016_j_jmgm_2021_108028 crossref_primary_10_1016_j_phymed_2020_153440 crossref_primary_10_1371_journal_pone_0282961 crossref_primary_10_1080_17476348_2022_2128770 crossref_primary_10_18502_sjms_v17i4_12550 crossref_primary_10_1001_jamanetworkopen_2021_44942 crossref_primary_10_3390_v14010106 crossref_primary_10_1038_s41598_021_02432_7 crossref_primary_10_1016_j_isci_2020_101297 crossref_primary_10_47470_0869_7922_2022_30_2_122_127 crossref_primary_10_12688_f1000research_25593_1 crossref_primary_10_3390_ijms23094576 crossref_primary_10_3390_ijms21217937 crossref_primary_10_1186_s41120_023_00072_x crossref_primary_10_1016_j_coviro_2021_06_004 crossref_primary_10_1097_INF_0000000000003576 crossref_primary_10_23736_S0031_0808_21_04595_X crossref_primary_10_3389_fphar_2022_974849 crossref_primary_10_1021_acsptsci_0c00131 crossref_primary_10_1073_pnas_2024302118 crossref_primary_10_1007_s00011_020_01422_1 crossref_primary_10_1016_j_ygeno_2020_12_041 crossref_primary_10_1007_s00204_023_03529_w crossref_primary_10_1002_jmv_28157 crossref_primary_10_1371_journal_pone_0256401 crossref_primary_10_1021_acschemneuro_1c00019 crossref_primary_10_3390_vaccines10081284 crossref_primary_10_1021_acs_jcim_1c00384 crossref_primary_10_3390_v13010008 crossref_primary_10_3389_fphar_2020_01013 crossref_primary_10_1002_anie_202205858 crossref_primary_10_1016_j_ijbiomac_2022_12_057 crossref_primary_10_1128_mBio_02754_20 crossref_primary_10_1164_rccm_202111_2547PP crossref_primary_10_1016_j_jddst_2024_105384 crossref_primary_10_1186_s12931_022_02265_6 crossref_primary_10_1016_j_celrep_2021_108940 crossref_primary_10_1111_bph_15094 crossref_primary_10_1016_j_ijpharm_2025_125302 crossref_primary_10_1146_annurev_pharmtox_061220_093932 crossref_primary_10_1177_1934578X231212835 crossref_primary_10_3390_molecules28072989 crossref_primary_10_1016_j_isci_2021_102367 crossref_primary_10_1038_s41467_022_32565_w crossref_primary_10_3390_nu15153443 crossref_primary_10_1021_acsomega_3c05900 crossref_primary_10_1002_med_21940 crossref_primary_10_1073_pnas_2021579118 crossref_primary_10_1038_s41598_021_84053_8 crossref_primary_10_1021_acsptsci_0c00112 crossref_primary_10_4103_lungindia_lungindia_268_22 crossref_primary_10_1021_acs_jmedchem_4c01639 crossref_primary_10_1155_2022_2044282 crossref_primary_10_1039_D3MD00493G crossref_primary_10_1016_j_ejmech_2024_116442 crossref_primary_10_1039_D0CS01065K crossref_primary_10_22159_ijap_2023v15i1_45850 crossref_primary_10_1001_jamainternmed_2021_6759 crossref_primary_10_1038_s41421_020_00222_5 crossref_primary_10_1016_j_molstruc_2021_132010 crossref_primary_10_1080_22221751_2020_1791737 crossref_primary_10_4062_biomolther_2022_037 crossref_primary_10_1016_j_lanepe_2021_100084 crossref_primary_10_1128_JVI_02374_20 crossref_primary_10_1080_14787210_2021_1860020 crossref_primary_10_1016_j_biopha_2021_111544 crossref_primary_10_1073_pnas_2014441117 crossref_primary_10_1016_j_ijpharm_2022_122042 crossref_primary_10_3390_v15020568 crossref_primary_10_1016_j_antiviral_2022_105473 crossref_primary_10_3389_fendo_2022_829879 crossref_primary_10_1186_s12964_023_01376_x crossref_primary_10_3389_fcimb_2020_560240 crossref_primary_10_3389_fimmu_2020_586572 crossref_primary_10_1155_2022_8508489 crossref_primary_10_3390_v15020452 crossref_primary_10_1002_ange_202205858 crossref_primary_10_3389_fimmu_2023_1167639 crossref_primary_10_1016_j_antiviral_2022_105360 crossref_primary_10_1016_j_antiviral_2021_105188 crossref_primary_10_1186_s40360_022_00580_8 crossref_primary_10_1248_yakushi_20_00169 crossref_primary_10_1038_s41418_021_00844_6 crossref_primary_10_1016_j_phyplu_2021_100058 crossref_primary_10_3390_biomedicines11072019 crossref_primary_10_1080_17512433_2022_2113388 crossref_primary_10_1042_BST20200967 crossref_primary_10_3389_fphar_2020_592737 crossref_primary_10_1093_bioinformatics_btad244 crossref_primary_10_1007_s11418_021_01575_1 crossref_primary_10_3390_ijms21228803 crossref_primary_10_1016_j_jep_2021_113869 crossref_primary_10_3389_fphar_2023_1099425 crossref_primary_10_1021_acsinfecdis_1c00017 crossref_primary_10_1007_s43440_020_00132_z crossref_primary_10_1016_j_cbi_2024_110886 crossref_primary_10_1128_spectrum_01679_23 crossref_primary_10_1155_2021_1828792 crossref_primary_10_1016_j_ejmech_2023_115923 crossref_primary_10_2174_1566524021666211013121831 crossref_primary_10_1021_acsinfecdis_2c00091 crossref_primary_10_3390_microorganisms10071284 crossref_primary_10_1021_acsptsci_4c00512 crossref_primary_10_3390_chemistry4020019 crossref_primary_10_2174_1566524023666230613141746 crossref_primary_10_1590_1678_4685_gmb_2020_0198 crossref_primary_10_1002_jmv_27683 crossref_primary_10_3389_fmicb_2020_01818 crossref_primary_10_2169_naika_110_2085 crossref_primary_10_1038_s41467_021_21992_w crossref_primary_10_1039_D0RA09858B crossref_primary_10_1002_2211_5463_13153 crossref_primary_10_1002_adbi_202300511 crossref_primary_10_1038_s41587_022_01474_0 crossref_primary_10_1002_med_21870 crossref_primary_10_1007_s11033_021_06770_7 crossref_primary_10_1093_pnasnexus_pgac197 crossref_primary_10_3390_ijms22169057 crossref_primary_10_1007_s00284_023_03366_1 crossref_primary_10_2147_JAA_S337518 crossref_primary_10_3389_fmicb_2022_877813 crossref_primary_10_1124_jpet_120_000123 crossref_primary_10_3389_fddsv_2022_837587 crossref_primary_10_2174_1389200223666220315160835 crossref_primary_10_3390_cells9091962 crossref_primary_10_1042_BCJ20200514 crossref_primary_10_1002_med_21763 crossref_primary_10_1128_AAC_00020_21 crossref_primary_10_1134_S107042802105002X crossref_primary_10_1016_j_cct_2020_106176 crossref_primary_10_1016_j_ejmcr_2024_100173 crossref_primary_10_3390_molecules27144327 crossref_primary_10_1016_j_matchemphys_2023_128219 crossref_primary_10_3390_v16060863 crossref_primary_10_1039_D1NJ02955J crossref_primary_10_3389_fgene_2022_866474 crossref_primary_10_1016_j_patter_2020_100090 crossref_primary_10_1002_mco2_254 crossref_primary_10_2147_JAA_S354082 crossref_primary_10_1371_journal_pone_0246803 crossref_primary_10_1183_16000617_0199_2020 crossref_primary_10_1371_journal_pntd_0010363 crossref_primary_10_1111_gtc_12945 crossref_primary_10_1111_cts_13865 crossref_primary_10_1002_jcc_26512 crossref_primary_10_3390_v13020354 crossref_primary_10_1021_acs_jpclett_0c01579 crossref_primary_10_1080_07391102_2023_2278077 crossref_primary_10_7759_cureus_71867 crossref_primary_10_1002_pds_5345 crossref_primary_10_1038_s41586_021_03491_6 crossref_primary_10_1186_s12985_021_01624_x crossref_primary_10_1002_iid3_922 crossref_primary_10_3390_jcm10163567 crossref_primary_10_1128_aac_00956_23 crossref_primary_10_1371_journal_pone_0252576 crossref_primary_10_1007_s11095_021_03112_x crossref_primary_10_3390_molecules27185988 crossref_primary_10_1002_jmv_26397 crossref_primary_10_1021_acsomega_3c00724 crossref_primary_10_1016_j_jiac_2022_10_008 crossref_primary_10_1002_mco2_115 crossref_primary_10_1016_j_virusres_2023_199105 crossref_primary_10_2142_biophysico_bppb_v18_025 crossref_primary_10_21518_2079_701X_2021_16_92_98 crossref_primary_10_12688_f1000research_143776_2 crossref_primary_10_3390_ph14040357 crossref_primary_10_3390_pathogens10111514 crossref_primary_10_1016_j_bpj_2021_01_012 crossref_primary_10_1016_j_virusres_2023_199258 crossref_primary_10_1016_j_cmi_2022_02_031 crossref_primary_10_3390_jcm10163545 crossref_primary_10_3389_fphar_2022_835136 crossref_primary_10_1371_journal_ppat_1010171 crossref_primary_10_7554_eLife_65543 crossref_primary_10_1038_s42256_021_00335_w crossref_primary_10_1016_j_ajogmf_2020_100159 crossref_primary_10_1016_j_ejmech_2020_112862 crossref_primary_10_1016_j_cbd_2023_101122 crossref_primary_10_1002_ejoc_202100328 crossref_primary_10_1128_mbio_03347_21 crossref_primary_10_3390_antibiotics10111372 crossref_primary_10_4103_2311_8571_353502 crossref_primary_10_1109_TMI_2022_3178523 crossref_primary_10_4014_jmb_2110_10029 crossref_primary_10_1016_j_jbc_2023_105341 crossref_primary_10_3390_ijms22041581 crossref_primary_10_1016_j_antiviral_2023_105575 crossref_primary_10_1093_bib_bbac073 crossref_primary_10_1128_Spectrum_00472_21 crossref_primary_10_1016_j_scitotenv_2021_145740 crossref_primary_10_1021_acs_jnatprod_0c01324 crossref_primary_10_1002_jmv_27719 crossref_primary_10_1371_journal_pbio_3000970 crossref_primary_10_1016_j_bbrc_2020_10_094 crossref_primary_10_1016_j_jaci_2020_05_033 crossref_primary_10_1136_bmj_2021_068060 crossref_primary_10_3390_ijms22115672 crossref_primary_10_1128_JVI_01648_20 crossref_primary_10_3389_fphar_2021_771555 crossref_primary_10_4103_lungindia_lungindia_473_20 crossref_primary_10_15252_emmm_202013426 crossref_primary_10_1007_s00396_023_05120_2 crossref_primary_10_1016_j_antiviral_2020_104866 crossref_primary_10_1016_j_antiviral_2020_104988 crossref_primary_10_1016_j_celrep_2021_109218 crossref_primary_10_1093_nar_gkaa969 crossref_primary_10_1186_s12948_021_00159_4 crossref_primary_10_3390_molecules29112524 crossref_primary_10_1136_bcr_2020_236812 crossref_primary_10_3390_jpm11060556 crossref_primary_10_3390_ijms22126574 crossref_primary_10_1016_j_ijantimicag_2020_106274 crossref_primary_10_1016_j_isci_2022_105254 crossref_primary_10_3390_biomedicines9060689 crossref_primary_10_1021_acs_jnatprod_3c00159 crossref_primary_10_1038_s41598_020_77003_3 crossref_primary_10_1016_j_nbd_2021_105422 crossref_primary_10_1371_journal_ppat_1010498 crossref_primary_10_1007_s42860_021_00153_6 crossref_primary_10_1021_acsmedchemlett_0c00298 crossref_primary_10_1038_s41419_022_05447_8 crossref_primary_10_1016_j_ijpharm_2021_120611 crossref_primary_10_1055_a_1291_7692 crossref_primary_10_1177_08850666211053548 crossref_primary_10_1016_j_antiviral_2020_104990 crossref_primary_10_1186_s13195_020_00744_w crossref_primary_10_1016_j_virs_2023_01_008 crossref_primary_10_1016_j_ijbiomac_2020_12_020 crossref_primary_10_1016_j_jchromb_2021_122862 crossref_primary_10_1371_journal_pone_0303924 crossref_primary_10_3390_molecules27030683 crossref_primary_10_1128_spectrum_01504_21 crossref_primary_10_1016_j_fitote_2024_106112 crossref_primary_10_3390_pharmaceutics16101288 crossref_primary_10_1016_j_csbj_2021_04_014 crossref_primary_10_1136_bmjebm_2021_111788 crossref_primary_10_3390_molecules26041100 crossref_primary_10_3390_v13112306 crossref_primary_10_2174_1574885517666220428095207 crossref_primary_10_3390_ijms22126551 crossref_primary_10_1038_s41598_023_31276_6 crossref_primary_10_3389_fpubh_2022_948520 crossref_primary_10_1007_s11224_022_01975_3 crossref_primary_10_3390_v16040640 crossref_primary_10_1007_s13402_021_00603_2 crossref_primary_10_1002_prot_26164 crossref_primary_10_1016_j_bbadis_2021_166294 crossref_primary_10_3390_molecules28166142 crossref_primary_10_1371_journal_pone_0307154 crossref_primary_10_1016_j_addr_2021_113848 crossref_primary_10_1016_S2213_2600_20_30447_1 crossref_primary_10_1016_j_bmcl_2020_127667 crossref_primary_10_3390_molecules26134005 crossref_primary_10_35772_ghm_2020_01082 crossref_primary_10_3389_fmolb_2021_628144 crossref_primary_10_1016_j_cyto_2024_156756 |
| Cites_doi | 10.1002/cpt1976196802 10.1016/j.jiac.2020.04.007 10.1038/s41467-019-13659-4 10.1101/2020.01.31.929547 10.1056/NEJMoa2001316 10.1101/2020.03.11.987016 10.1038/d41586-020-00444-3 10.1038/s41422-020-0282-0 10.1038/nrd1468 10.1021/acsinfecdis.0c00052 10.1128/AAC.48.7.2693-2696.2004 10.1038/s41586-020-2012-7 10.2147/jaa.s4651 10.1101/2020.02.19.20025163 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 American Society for Microbiology. Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology |
| Copyright_xml | – notice: Copyright © 2020 American Society for Microbiology. – notice: Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1128/AAC.00819-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Antiviral Drug Candidates against SARS-CoV-2, Jeon et al Antiviral Drug Candidates against SARS-CoV-2 |
| EISSN | 1098-6596 |
| ExternalDocumentID | PMC7318052 00819-20 32366720 10_1128_AAC_00819_20 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: National Research Foundation of Korea (NRF) grantid: NRF-2017M3A9G6068245; NRF-2020M3E9A1041756 funderid: https://doi.org/10.13039/501100003725 – fundername: ; grantid: NRF-2017M3A9G6068245; NRF-2020M3E9A1041756 |
| GroupedDBID | --- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO O9- OK1 P2P RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7X8 5PM |
| ID | FETCH-LOGICAL-a484t-68df5458d74c63874fa05f5ccc110673be59d3ccb56cad821dc1b8f341a18eec3 |
| ISSN | 0066-4804 1098-6596 |
| IngestDate | Thu Aug 21 18:13:37 EDT 2025 Fri Sep 05 06:21:50 EDT 2025 Tue Dec 28 13:59:20 EST 2021 Mon Jul 21 06:02:16 EDT 2025 Thu Apr 24 23:10:41 EDT 2025 Tue Jul 01 04:13:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | COVID-19 FDA-approved drug SARS-CoV-2 |
| Language | English |
| License | Copyright © 2020 American Society for Microbiology. All Rights Reserved. This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. https://doi.org/10.1128/ASMCopyrightv2 All Rights Reserved. This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a484t-68df5458d74c63874fa05f5ccc110673be59d3ccb56cad821dc1b8f341a18eec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 64:e00819-20. https://doi.org/10.1128/AAC.00819-20. Sangeun Jeon and Meehyun Ko contributed equally to this work. Author order was determined alphabetically. |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7318052 |
| PMID | 32366720 |
| PQID | 2398631162 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7318052 proquest_miscellaneous_2398631162 asm2_journals_10_1128_AAC_00819_20 pubmed_primary_32366720 crossref_primary_10_1128_AAC_00819_20 crossref_citationtrail_10_1128_AAC_00819_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200623 |
| PublicationDateYYYYMMDD | 2020-06-23 |
| PublicationDate_xml | – month: 6 year: 2020 text: 20200623 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_7_2 e_1_3_2_6_2 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 Zhou, P, Yang, X-L, Wang, X-G, Hu, B, Zhang, L, Zhang, W, Si, H-R, Zhu, Y, Li, B, Huang, C-L, Chen, H-D, Chen, J, Luo, Y, Guo, H, Jiang, R-D, Liu, M-Q, Chen, Y, Shen, X-R, Wang, X, Zheng, X-S, Zhao, K, Chen, Q-J, Deng, F, Liu, L-L, Yan, B, Zhan, F-X, Wang, Y-Y, Xiao, G-F, Shi, Z-L (B1) 2020; 579 Mizumoto, K, Chowell, G (B2) 2020 Wu, C-J, Jan, J-T, Chen, C-M, Hsieh, H-P, Hwang, D-R, Liu, H-W, Liu, C-Y, Huang, H-W, Chen, S-C, Hong, C-F, Lin, R-K, Chao, Y-S, Hsu, J (B8) 2004; 48 B12 B14 Wang, M, Cao, R, Zhang, L, Yang, X, Liu, J, Xu, M, Shi, Z, Hu, Z, Zhong, W, Xiao, G (B6) 2020; 30 Smith, TC, Kinkel, AW, Gryczko, CM, Goulet, JR (B10) 1976; 19 Gassen, NC, Niemeyer, D, Muth, D, Corman, VM, Martinelli, S, Gassen, A, Hafner, K, Papies, J, Mösbauer, K, Zellner, A, Zannas, AS, Herrmann, A, Holsboer, F, Brack-Werner, R, Boshart, M, Müller-Myhsok, B, Drosten, C, Müller, MA, Rein, T (B9) 2019; 10 Li, Q, Guan, X, Wu, P, Wang, X, Zhou, L, Tong, Y, Ren, R, Leung, KSM, Lau, EHY, Wong, JY, Xing, X, Xiang, N, Wu, Y, Li, C, Chen, Q, Li, D, Liu, T, Zhao, J, Liu, M, Tu, W, Chen, C, Jin, L, Yang, R, Wang, Q, Zhou, S, Wang, R, Liu, H, Luo, Y, Liu, Y, Shao, G, Li, H, Tao, Z, Yang, Y, Deng, Z, Liu, B, Ma, Z, Zhang, Y, Shi, G, Lam, TTY, Wu, JT, Gao, GF, Cowling, BJ, Yang, B, Leung, GM, Feng, Z (B3) 2020; 382 Schaffner, TJ, Skoner, DP (B11) 2009; 2 Ashburn, TT, Thor, KB (B4) 2004; 3 Maxmen, A (B5) 2020; 578 Xu, J, Shi, P-Y, Li, H, Zhou, J (B7) 2020 Iwabuchi, K, Yoshie, K, Kurakami, Y, Takahashi, K, Kato, Y, Morishima, T (B13) 2020; 26 |
| References_xml | – ident: e_1_3_2_11_2 doi: 10.1002/cpt1976196802 – ident: e_1_3_2_14_2 doi: 10.1016/j.jiac.2020.04.007 – ident: e_1_3_2_10_2 doi: 10.1038/s41467-019-13659-4 – ident: e_1_3_2_15_2 doi: 10.1101/2020.01.31.929547 – ident: e_1_3_2_4_2 doi: 10.1056/NEJMoa2001316 – ident: e_1_3_2_13_2 doi: 10.1101/2020.03.11.987016 – ident: e_1_3_2_6_2 doi: 10.1038/d41586-020-00444-3 – ident: e_1_3_2_7_2 doi: 10.1038/s41422-020-0282-0 – ident: e_1_3_2_5_2 doi: 10.1038/nrd1468 – ident: e_1_3_2_8_2 doi: 10.1021/acsinfecdis.0c00052 – ident: e_1_3_2_9_2 doi: 10.1128/AAC.48.7.2693-2696.2004 – ident: e_1_3_2_2_2 doi: 10.1038/s41586-020-2012-7 – ident: e_1_3_2_12_2 doi: 10.2147/jaa.s4651 – ident: e_1_3_2_3_2 doi: 10.1101/2020.02.19.20025163 – volume: 579 start-page: 270 year: 2020 end-page: 273 ident: B1 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 – volume: 30 start-page: 269 year: 2020 end-page: 271 ident: B6 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res doi: 10.1038/s41422-020-0282-0 – volume: 2 start-page: 25 year: 2009 end-page: 32 ident: B11 article-title: Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma publication-title: J Asthma Allergy doi: 10.2147/jaa.s4651 – volume: 26 start-page: 625 year: 2020 end-page: 632 ident: B13 article-title: Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases publication-title: J Infect Chemother doi: 10.1016/j.jiac.2020.04.007 – year: 2020 ident: B2 article-title: Estimating the risk of 2019 novel coronavirus death during the course of the outbreak in China, 2020 publication-title: medRxiv doi: 10.1101/2020.02.19.20025163 – year: 2020 ident: B7 article-title: Broad spectrum antiviral agent niclosamide and its therapeutic potential publication-title: ACS Infect Dis doi: 10.1021/acsinfecdis.0c00052 – ident: B12 article-title: Matsuyama S , Kawase M , Nao N , Shirato K , Ujike M , Kamitani W , Shimojima M , Fukushi S . 2020 . The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 . bioRxiv . doi: 10.1101/2020.03.11.987016 . – volume: 578 start-page: 347 year: 2020 end-page: 348 ident: B5 article-title: More than 80 clinical trials launch to test coronavirus treatments publication-title: Nature doi: 10.1038/d41586-020-00444-3 – volume: 19 start-page: 802 year: 1976 end-page: 806 ident: B10 article-title: Absorption of pyrvinium pamoate publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1976196802 – ident: B14 article-title: Beck BR , Shin B , Choi Y , Park S , Kang K . 2020 . Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model . bioRxiv . doi: 10.1101/2020.01.31.929547 . – volume: 48 start-page: 2693 year: 2004 end-page: 2696 ident: B8 article-title: Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.7.2693-2696.2004 – volume: 382 start-page: 1199 year: 2020 end-page: 1207 ident: B3 article-title: Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia publication-title: N Engl J Med doi: 10.1056/NEJMoa2001316 – volume: 10 start-page: 5770 year: 2019 ident: B9 article-title: SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection publication-title: Nat Commun doi: 10.1038/s41467-019-13659-4 – volume: 3 start-page: 673 year: 2004 end-page: 683 ident: B4 article-title: Drug repositioning: identifying and developing new uses for existing drugs publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1468 |
| SSID | ssj0006590 |
| Score | 2.7080052 |
| Snippet | Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against... |
| SourceID | pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Animals Anti-Inflammatory Agents - pharmacology Antiviral Agents Antiviral Agents - pharmacology Betacoronavirus Betacoronavirus - drug effects Cell Line Chlorocebus aethiops Coronavirus Infections Coronavirus Infections - drug therapy COVID-19 Drug Evaluation, Preclinical - methods Drug Repositioning Editor's Pick Humans Niclosamide Niclosamide - pharmacology Pandemics Pneumonia, Viral Pneumonia, Viral - drug therapy Pregnenediones Pregnenediones - pharmacology SARS-CoV-2 Vero Cells |
| Title | Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32366720 https://journals.asm.org/doi/10.1128/AAC.00819-20 https://www.proquest.com/docview/2398631162 https://pubmed.ncbi.nlm.nih.gov/PMC7318052 |
| Volume | 64 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBahY6UvY8tu2Q1tbH1JncayZNmPxl0Jg4ywtKVvxpLlxLA4pY4H2W_Yj54uvqUX2Poigi3ZJufz8ZF0vu8A8JmiBAviuRbzqd5mFFacOsLymZ0Q7DhExIooPP3uTs7xt0ty2ev96WQtlRs24r_v5JU8xKrymLSrYsn-h2Wbi8oD8re0r2ylhWX7TzY2LNu0WnbTQWWuqkEo0v3JdbkYhoq0oub0xTBexJkMBYfz4MfcCtcXFjLUktOTwAqUsPgvGXqqQUU3XlXXW2VarEmJCiw0H05T4ZZiVZG32iwcYbbw54qwULbb-3o1dirEclveSgDKltsGWuFynRmftRSiuxyBVNUayzCGOwwA5Zo6SafTrBWV6jpj17WwZ6oPj4Txv0re1CWmyG3toI3MeQVEerffR4rLEAThSMc4libYbToQuFppDDjIcV1qzt7Q2Z5NQyod3JjID_ojRKne9J9M2smUfCxDaKoeu6ZRIO-4e-MDsF_fRX7m42KFdkOeW_OYm-m4nfjm7Cl4Uk1MYGBQ9gz0RN4Hj02p0m0f7E-rJIw-OJwZufPtETxr2XvFETyEs1YIffscXOziE65T2OATKqjBFp-wwids8QkVPmEXn3pQ8QKcn349CydWVcfDirGHN5brJanan00o5tLdU5zGY5ISzrmtBAwdJoifOJwz4vI48ZCdcJt5qYyvYtsTgjsvwV6-zsVrACn3PZY6LJUN5gwzRD3CEo4JE77w8QB8Uv94VL2kRaTnuMiLpIUibaEIjQdgWNsj4pUSvirI8vOe3l-a3ldGAeaefh9r00bSRat9tzgX67KIlMSm69i2iwbglTF1c6UaKgNAd0DQdFDy77tn8mypZeArtL558Mi34KB9g9-Bvc11Kd7LEHvDPmjk_wXQM9Bt |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+Antiviral+Drug+Candidates+against+SARS-CoV-2+from+FDA-Approved+Drugs&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Jeon%2C+Sangeun&rft.au=Ko%2C+Meehyun&rft.au=Lee%2C+Jihye&rft.au=Choi%2C+Inhee&rft.date=2020-06-23&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=64&rft.issue=7&rft_id=info:doi/10.1128%2FAAC.00819-20&rft_id=info%3Apmid%2F32366720&rft.externalDocID=PMC7318052 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |